1. Darras BT, Jones HR. Diagnosis of pediatric
neuromuscular disorders in the era of DNA analysis. Pediatr
Neurol. 2000;23(4):289-300.
2. Okinaka S, Sugita H, Momoi H, et al. Serum creatine phosphokinase
and aldolase activity in neuromuscular disorders.
Trans
Am Neurol Assoc. 1959;84:62-64.
[PubMed: 13854172]
3. Okinaka S, Kumagai H, Ebashi S, et al. Serum creatine phosphokinase.
Activity in progressive muscular dystrophy and neuromuscular diseases.
Arch
Neurol. 1961;4:520-525.
[PubMed: 13730599]
4. Sibley JA, Lehninger AL. Aldolase in the serum and tissue
of tumor-bearing animals. J Natl Cancer Inst. 1949;9(4):303-309.
5. Dubowitz V. Muscle Biopsy: A Practical Approach.
London: Bailliere Tindall; 1985.
6. Arahata K, Ishiura S, Ishiguro T, et al. Immunostaining of
skeletal and cardiac muscle surface membrane with antibody against Duchenne
muscular dystrophy peptide.
Nature. 1988; 333(6176):861-863.
[PubMed: 3290683]
7. Bonilla E, Samitt CE, Miranda AF, et al. Duchenne muscular
dystrophy: deficiency of dystrophin at the muscle cell surface. Cell. 1988;54(4):447-452.
8. Zubrzycka-Gaarn EE, Bulman DE, Karpati G, et al. The Duchenne
muscular dystrophy gene product is localized in sarcolemma of human
skeletal muscle. Nature. 1988;333(6172):466-469.
9. Kang PB. Pediatric nerve conduction studies and electromyography.
In: Blum AS, Rutkove SB, eds. The Clinical Neurophysiology Primer.
Totowa, NJ: Humana Press; 2007:369-389.
10. Jones HR, Bolton CF, Harper CM, Harmon RL. Pediatric
Clinical Electromyography. Philadelphia: Lippincott Williams
& Wilkins; 1996.
11. Lewis RA, Sumner AJ. The electrodiagnostic distinctions
between chronic familial and acquired demyelinative neuropathies. Neurology. 1982;32(6):592-596.
12. Miller RG, Gutmann L, Lewis RA, Sumner AJ. Acquired versus familial
demyelinative neuropathies in children. Muscle Nerve. 1985;8(3):205-210.
13. Cameron CL, Kang PB, Burns TM, Darras BT, Jones HR, Jr.
Multifocal slowing of nerve conduction in metachromatic leukodystrophy. Muscle
Nerve. 2004;29(4):531-536.
14. Lorenzetti D, Pareyson D, Sghirlanzoni A, et al. A 1.5-Mb deletion
in 17p11.2-p12 is frequently observed in Italian families with hereditary
neuropathy with liability to pressure palsies. Am J Hum
Genet. 1995;56(1):91-98.
15. Lupski JR, Chance PF, Garcia CA. Inherited primary peripheral neuropathies.
Molecular genetics and clinical implications of CMT1A and HNPP. JAMA. 1993;270(19):2326-2330.
16. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication
associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66(2):219-232.
17. Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98% of
DMD/BMD gene deletions by polymerase chain reaction. Hum
Genet. 1990;86(1):45-48.
18. Chamberlain JS, Farwell NJ, Chamberlain JR, Cox GA, Caskey CT.
PCR analysis of dystrophin gene mutation and expression. J
Cell Biochem. 1991;46(3):255-259.
19. Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT.
Deletion screening of the Duchenne muscular dystrophy locus via
multiplex DNA amplification.
Nucleic Acids Res. 1988;
16(23):11141-11156.
[PubMed: 3205741]
20. Oudet C, Hanauer A, Clemens P, Caskey T, Mandel JL. Two
hot spots of recombination in the DMD gene correlate with the deletion
prone regions. Hum Mol Genet. 1992;1(8):599-603.
21. Roa BB, Garcia CA, Suter U, et al. Charcot-Marie-Tooth disease type
1A. Association with a spontaneous point mutation in the PMP22 gene. N
Engl J Med. 1993;329(2):96-101.